The HIV envelope (Env) protein gp120 is protected from antibody recognition by a dense glycan shield. However, several of the recently identified PGT broadly neutralizing antibodies appear to interact directly with the HIV glycan coat. Crystal structures of antigen-binding fragments (Fabs) PGT 127 and 128 with Man 9 at 1.65 and 1.29 angstrom resolution, respectively, and glycan binding data delineate a specific high mannose-binding site. Fab PGT 128 complexed with a fully glycosylated gp120 outer domain at 3.25 angstroms reveals that the antibody penetrates the glycan shield and recognizes two conserved glycans as well as a short b-strand segment of the gp120 V3 loop, accounting for its high binding affinity and broad specificify. Furthermore, our data suggest that the high neutralization potency of PGT 127 and 128 immunoglobulin Gs may be mediated by cross-linking Env trimers on the viral surface.
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The HIV envelope (Env) protein gp120 is protected from antibody recognition by a dense glycan shield. However, several of the recently identified PGT broadly neutralizing antibodies appear to interact directly with the HIV glycan coat. Crystal structures of antigen-binding fragments (Fabs) PGT 127 and 128 with Man 9 at 1.65 and 1.29 angstrom resolution, respectively, and glycan binding data delineate a specific high mannose-binding site. Fab PGT 128 complexed with a fully glycosylated gp120 outer domain at 3.25 angstroms reveals that the antibody penetrates the glycan shield and recognizes two conserved glycans as well as a short b-strand segment of the gp120 V3 loop, accounting for its high binding affinity and broad specificify. Furthermore, our data suggest that the high neutralization potency of PGT 127 and 128 immunoglobulin Gs may be mediated by cross-linking Env trimers on the viral surface.
V
iruses have evolved a variety of mechanisms to escape antibody recognition, many of which involve features of the viral surface proteins, such as high variability, steric occlusion, and glycan coating. For HIV, the dense shield of glycans (1, 2) that decorate the viral Env protein was once believed to be refractory to antibody recognition, masking conserved functionally significant protein epitopes for which greater exposure would result in increased susceptibility to antibody neutralization. However, the broadly neutralizing monoclonal antibody (bnmAb) 2G12 and several of the recently described PGT antibodies appear to bind directly to the HIV glycan coat. Although carbohydrateprotein interactions are typically weak (3), 2G12 recognizes terminal dimannose (Mana1,2Man) moieties on oligomannose glycans, using an unusual domain-exchanged antibody structure that creates a multivalent binding surface that enhances the affinity of the interaction through avidity effects (4). However, although 2G12 neutralizes clade B isolates broadly, it is less effective against other clades, particularly clade C viruses, which have a somewhat different oligomannose glycan arrangement than clade B viruses. In contrast, we have recently isolated six bnmAbs (PGTs 125 to 128, 130, and 131) that bind specifically to the Man 8/9 glycans on gp120 and potently neutralize across clades (5) . PGT 128, the broadest of these antibodies, neutralizes over 70% of globally circulating viruses and is, on average, an order of magnitude more potent than the recently described PG9, PG16, VRC01, and PGV04 (also known as VRC-PG04) bnmAbs (5) (6) (7) (8) and is two orders of magnitude more potent than prototype bnmAbs described earlier (6, 9) .
The neutralization potency exhibited by the PGT class of antibodies suggests that they may provide protection at relatively low serum concentrations. Hence, the epitopes recognized by these antibodies may be good vaccine targets if appropriate immunogens can be designed.
Crystal structures of PGTs 127 and 128 bound to Man 9 . To gain a structural understanding of the specificity for Man 8/9 glycans by PGTs 127 and 128, we first determined crystal structures of the Fabs of PGTs 127 and 128 with a synthetic Man 9 glycan lacking the core N-acetylglucosamine (GlcNAc) moieties at 1.65 and 1.29 Å resolution, respectively (table S1). The bound glycan is well ordered, except for the terminal mannose residue of the D2 arm ( Fig. 1 and figs. S1 and S2A). The 127/Man 9 and 128/Man 9 structures show a similar conformation for the glycan ( fig. S1 ), demonstrating a conserved mode of recognition by these clonally related antibodies.
Analysis of these crystal structures reveals the origin of their specificity for Man 8/9 glycans. The terminal mannose residues of both the D1 and D3 arms, which are only present on Man 8/9 glycans (Fig. 1B, Fig. 2A, and fig. S2A ), are heavily contacted, forming 11 of the 16 total hydrogen-bonding interactions with the antibody (table S2) . This specificity for glycans is consistent with glycan array data showing binding of PGT 127 and 128 to Man 8 and Man 9 , but not to monoglucosylated Man 9 N-glycans (fig. S3A), and with glycosidase inhibitor specificity Fig. 1 . Binding mode of Man 9 by antibody PGT 128 revealed by the high-resolution crystal structure of the complex. (A) Front (top) and side (bottom) views of PGT 128 Fab with bound Man 9 glycan. The light and heavy chains are depicted as gray and magenta ribbons, respectively, and the glycan as yellow (carbons) and red (oxygen) ball-and-stick models. (B) Close-up view of glycan binding site of PGT 128 showing electron density (2Fo-Fc) at 1.0s for glycan and associated water molecules. Water molecules are shown as red spheres with the electron density colored red for waters that bridge mannose residues and green for waters in the glycan-antibody interface. (C) Detailed view of the interactions in the Man 9 glycanbinding site at the interface of CDRs H2, H3, L3, and FR2. Tryptophan (V H W52f, W56, and W100e and V L W95) and Asn/Asp (V H N53 and V L N94 and D95a) residues from the Fab are enriched at the interface and dominate the interactions with the glycan. The D1 arm is bound by residues in the six-amino acid CDR H2 insert and V H FR2. The D3 arm is bound by residues within CDR L3. Hydrogen bonds are shown as green dashes. , makes van der Waals and hydrogenbonding contacts to one side of an extended b-strand region of PGT 128 CDR H3, which includes L100-D100d. The V3 base is intercalated between the apex of the CDR H2 insert (Y52e and W52f) and CDR H3.
profiling ( fig. S3B) 9 , particularly at the tip of the D1 arm (4).
Crystal structure of PGT 128 bound to a glycosylated gp120 outer domain. To structurally define the epitope recognized by PGT 128 in the context of gp120, we cocrystallized Fab PGT 128 with a glycosylated gp120 outer domain construct containing a truncated V3 loop [engineered outer domain mini-V3 (eODmV3) (14)] ( fig. S6 ). PGT 128 binds to eODmV3 with an apparent affinity of 46 nM, which is about eightfold less than its interaction with the HIV-1 JR-FL gp120 core with a full-length V3 ( fig. S7 ). The V3 loop truncation did not affect PGT 128 binding ( fig. S7 ). The purified complex was homogenous as assessed by size exclusion chromatography multiangle light scattering ( fig. S8 ), and the crystal structure was solved by molecular replacement and refined at 3.25 Å resolution to an R cryst of 0.21 and R free of 0.26 (table S1). H52aA results in a decrease in gp120 binding and neutralization, whereas disruption of the CDR H1-H2 disulfide (V H C32A or C52bA, or a double mutant) greatly compromises both gp120 binding and neutralization. There is much less effect on the glycan array, which primarily reflects binding to the primary glycan-binding site. A complete list of paratope mapping, as well as the effect on gp120 binding, is provided in table S3. (C) Contribution of the six-residue CDR H2 insert to neutralization and glycan binding. PGT 128 retains the ability to bind Man 8/9 and to neutralize to a lesser extent on deletion of the insert, whereas PGT 127 no longer neutralizes, although still has some ability to bind Man 8/9 . Swapping of the insert between 127 and 128 allows 128 to retain some binding and neutralization, but substantially reduces binding and abrogates neutralization when the PGT 128 H2 insert is transplanted onto PGT 127 (fig. S5 ).
The crystal structure unexpectedly revealed that PGT 128 engages two different glycans, as well as the C-terminal end of the V3 loop, within the binding site ( Fig. 2A) . The primary glycanbinding site is occupied by the high-mannose glycan attached to N332 (Man 8/9 GlcNAc 2 ), whereas a secondary glycan-binding site is occupied by electron density associated with N301 (Fig. 2B) . The secondary glycan-binding site is focused on the core pentasaccharide attached to N301, as only the Man 5 GlcNAc 2 portion of the glycan is visible in the density map. The two GlcNAc residues bind atop the CDR H1-H2 disulfide in a favorable hydrophobic interaction; hydrogen bonds are formed between the backbone amide and carbonyl of Ala 52c and the N-acetyl and O3 hydroxyl of the first Asn-linked GlcNAc. FR3 and CDR H1 residues form the contact site for the mannose sugars ( Fig. 2B and table S4 ).
The CDR H3 apex contacts the V3 loop on the gp120 outer domain (Fig. 2C) . The C-terminal residues of V3, Ile To assess the importance of the individual glycan binding sites for epitope recognition, we tested a series of antibody variants containing single amino acid substitutions in each subsite. Mutations in the primary glycan binding site (N332) compromised neutralization, gp120 binding, and binding to Man 8/9 on the glycan array ( Fig. 3A  and table S3 ). Although numerous interactions are made with the glycan, including a total of 16 hydrogen bonds, disruption of the bidentate interaction between Man D3 and CDR L3 Asp 95a resulted in a loss of gp120 and glycan binding and neutralizing activity (Fig. 3A) . The mutation of residues involved in the secondary site (N301), particularly the H1-H2 disulfide, also resulted in a loss of gp120 binding and virus neutralization ( Fig. 3B and table S3) . Nevertheless, the affinity of this secondary site (N301) was too low to detect directly by glycan array, as evidenced by the lack of glycan binding capacity by a primary glycan-binding site loss-of-function variant (V L Asp 95a →Ala). Also, the mutation of FR3 and CDR H1 residues that interact with the mannose residues in the secondary binding site generally had little to no effect on neutralization by PGT 128, suggesting that these interactions are not as crucial as the GlcNAc interactions (table S3) . Notwithstanding, the N301 glycan is required for high-affinity binding to gp120 and neutralization. The importance of the N332 and N301 glycans in forming the PGT 128 epitope was confirmed by alanine scanning mutagenesis, where substitutions at positions 332 and 301 resulted in the loss of neutralizing activity against most isolates tested (table S5). PGT 127 displayed a similar glycan reactivity profile as PGT 128 against most isolates, suggesting that the two antibodies share a similar conserved mode of epitope recognition.
The N301 and N332 glycans are 93 and 73% conserved among HIV isolates ( fig. S9 ), respectively, which accounts for the ability of PGT 128 to neutralize 72% of circulating viruses. In the HIV-1 JR-CSF strain, individual alanine mutations at positions 332 and 301 had little to no effect on neutralization by PGT 128 (5), but various combinations of double glycan substitutions, which included the nearby N295 as well as N332 and N301, completely abolished neutralizing activity ( fig. S10 ). These results suggest that, for isolate JR-CSF, the epitope may be more promiscuous and accommodate antibody binding to two out of three glycans. The PGT 128 requirement for two closely spaced N-linked glycans (table S5 and fig. S10 ) probably accounts for its lack of reactivity with self-glycoproteins displaying single Man 8/9 GlcNAc 2 sugars ( fig. S11 ) and for the resistance of HIV-2 and SIV viruses to neutralization ( fig. S12 ). Specific interactions with V3 were more difficult to investigate, because the V3 contacts with PGT 128 CDR H3 are primarily mediated through backbone hydrogen bonding and van der Waals interactions that are tolerant of side-chain variation, as seen for the V3 crown-specific antibody 447-52D (16). Thus, three discontinuous sites on the gp120 outer domain (449 Å 2 from N332, 328 Å 2 from N301, and 305 Å 2 from V3) combine to form 1081 Å 2 of buried surface area (table S4) , which is similar in overall size to other anti-HIV bnmAbs VRC01 and PGV04/VRC-PG04, which bury 1229 Å 2 and 1080 Å 2 on the CD4 binding site of core gp120, respectively (8, 17) .
The PGT 128 epitope is accessible on the HIV trimer. To gain a structural understanding of the epitope recognized by PGT 128 in the context of the HIV trimer, we generated a negative stain reconstruction of a soluble, partially deglycosylated 664G trimer in complex with PGT 128 Fab. This engineered Env trimer incorporates stabilizing mutations that allow it to maintain integrity upon deglycosylation (18) (19) (20) (21) (22) (23) . Three Fabs bind to the trimer with no close contacts to neighboring gp120 protomers, indicating that the outer domain epitope is accessible and exposed (Fig. 4 and fig. S13 ). Fitting of the crystal structure of the PGT 128/eODmV3 complex into the reconstruction also revealed that the V3 base (Fig. 4A and fig. S13D ) is surface-exposed, but below and adjacent to the density corresponding to the V1/V2 loops. No large-scale conformational changes in the trimer appear to take place upon Fab binding (Fig. 4B) . Thus, the elements that form the PGT 128 epitope are almost directly opposite the CD4bs on gp120 and appear to be accessible and not subject to steric occlusion in the trimer. (30) . The putative location of V1/V2 is indicated. The V3 base, N301, and N332 are exposed on the surface of the outer domain and slightly below the trimer apex, which corresponds to the location of the V1/V2 loops. The PGT 128 epitope is located approximately on the opposite side of gp120 from the CD4bs (fig. S13C) .
Mechanism of exceptional neutralization potency by PGTs 127 and 128. Because a strong correlation has been described in other systems between antibody apparent binding affinity for native Env trimers expressed on the cell surface and neutralization potency (24-27), we first compared the neutralization potency of PGTs 127 and 128 to their binding affinity for cell-surfaceexpressed HIV-1 JR-FL Env trimers (28, 29) . The neutralization median inhibitory concentration (IC 50 ) values of PGT 127 and 128 immunoglobulin Gs (IgGs) against HIV-1 JR-FL were~17-and 31-fold lower (i.e., more potent neutralization) than their cell-surface trimer-binding median effective concentration (EC 50 ) values (Fig. 5) , whereas the neutralization potency of Fabs PGT 127 and 128 correlated strongly with their binding affinity for cell-surface HIV-1 JR-FL Env trimers (Fig. 5) . Furthermore, although PGT 127 and 128 IgGs bound with similar apparent affinity to cellsurface Env trimers as their Fab counterparts, they neutralized approximately 81-and 70-fold more potently, respectively, than their corresponding Fab fragments (Fig. 5) . Similar results were also obtained with HIV-1 YU2 (fig. S14 ). Collectively, these results suggest that PGT 127 and 128 IgGs may cross-link spikes on the surface of the virus, giving an increase in affinity through avidity effects, but not on the surface of Env-expressing cells. The comparable binding affinity of PGT 127 and 128 IgGs and Fabs for cell-surface Env is consistent with IgG cross-linking of trimers on the viral surface occurring between spikes rather than within a single spike. In addition, intraspike cross-linking by PGT 128 IgG appears unlikely based on the inter-Fab distances observed for PGT 128 Fab-trimer complexes by electron microscopy (EM) (Fig. 4) . Considering the scarcity of native Env trimers on the viral surface (30), a possible explanation for this observation is that two or more viral spikes are clustered to form an infectious unit, as proposed previously (31) . In this scenario, neutralization measures binding to infectious Env units but not to single spikes. This interpretation also requires few infectious units on transfected cells as compared to single spikes, and that the single spikes are not in close enough proximity for cross-linking to occur. Previous studies have reported that avidity generally plays a limited role in antibody neutralization of HIV, as suggested by the relatively modest increases in neutralization potencies of IgGs as compared to their Fab counterparts (32, 33) . However, in contrast to other broadly neutralizing epitopes on HIV Env, the epitopes recognized by PGTs 127 and 128 appear to be highly accessible (Fig. 4) , which may promote interspike cross-linking.
Previous studies in various virus systems, including murine leukemia virus, dengue virus (DENV), West Nile virus (WNV), poliovirus, and HIV, have shown that viral infectivity decays exponentially with time (34) (35) (36) . Furthermore, certain neutralizing antibodies have been shown to accelerate the decay of viral infectivity (37, 38) . For example, recent studies have demonstrated that the half-life of WNV and DENV decreases in the presence of virus-specific antibodies (37) . To determine whether PGTs 127 and 128 affect the rate of viral infectivity decay, we measured the half-life of HIV-1 JR-FL in the presence and absence of PGT 127 and 128 IgGs and Fabs. At antibody concentrations corresponding to 90% neutralization, PGTs 127 and 128 IgGs reduced the half-life of HIV-1 JR-FL by approximately 9.7-and 11.2-fold, respectively, whereas the corresponding Fab fragments and 2G12 IgG had little to no effect on viral infectivity decay (Fig. 6, A and B) . No evidence for antibody-induced gp120 shedding was observed ( fig. S15) . Collectively, these data suggest that interspike cross-linking by PGT 127 and 128 IgGs may accelerate the inactivation of HIV-1 JR-FL Env spikes, perhaps by inducing conformational changes that perturb trimer functionality (39) , resulting in enhanced neutralization potency.
Studies of protein-carbohydrate interactions have established various principles of molecular recognition. For example, spike glycan-protein interactions are weak because of unfavorable entropy contributions associated with glycan binding, multivalency is crucial to enhance binding affinity. Here we provide an example of multivalency achieved through the combination of glycan and protein; the three subsites for N332, N301, and the C-terminal V3 stem are essentially independent, but combine to mediate high-affinity recognition of a glycan-based epitope on HIV Env. Considering the highly exposed nature of this epitope and the high conservation of its two glycan and V3 loop backbone components, coupled with recent studies demonstrating that broad and potent serum neutralizing activity is frequently mediated by antibodies that target N332A-sensitive epitopes (5, (40) (41) (42) (43) , it appears that this antigenic region may serve as an attractive vaccine target if appropriate immunogens can be designed.
no. DE-AC02-06CH11357. GM/CA CAT has been funded in whole or in part with federal funds from NCI (grant Y1-CO-1020) and NIGMS (grant Y1-GM-1104 The origin of Galactic cosmic rays is a century-long puzzle. Indirect evidence points to their acceleration by supernova shockwaves, but we know little of their escape from the shock and their evolution through the turbulent medium surrounding massive stars. Gamma rays can probe their spreading through the ambient gas and radiation fields. The Fermi Large Area Telescope (LAT) has observed the star-forming region of Cygnus X. The 1-to 100-gigaelectronvolt images reveal a 50-parsec-wide cocoon of freshly accelerated cosmic rays that flood the cavities carved by the stellar winds and ionization fronts from young stellar clusters. It provides an example to study the youth of cosmic rays in a superbubble environment before they merge into the older Galactic population.
I sotopic and elemental abundances indicate that~20% of the cosmic-ray (CR) nuclei are synthesized by massive Wolf-Rayet stars at least 10 5 years before their acceleration, presumably by a supernova shockwave (1-3). Massive stars cluster in space and time (4) . Their supersonic winds and explosions power fast shockwaves and supersonic turbulence in the surrounding medium; thus, particle confinement and reacceleration by repeated shocks can substantially modify the CR properties before they diffuse at large in the Galaxy (5, 6) . This early diffusion can be followed in g rays as the young CRs interact with the gas and radiation surrounding stellar clusters.
The Cygnus X region boasts an abundance of massive stars born in the past few million years in numerous associations (7), notably in the massive Cyg OB2 cluster at a distance of 1.4 kpc (8, 9) .
The bright clusters have sculpted their parent molecular clouds over tens of parsecs (10, 11) through ionization, radiation pressure, and expansion of the coalescing stellar winds, creating lower-density cavities filled with neutral and ionized hydrogen from photodissociated H 2 . The compressed edges along the ionization fronts shine brightly in midinfrared as photon-dominated regions (PDRs) (Fig. 1) . The presence of the g Cygni supernova remnant in the region (12) and the detection of diffuse TeV emission by Milagro (13, 14) suggest the potential presence of young CRs. We probed their properties with Fermi Large Area Telescope (LAT) observations in the 0.1-to 100-GeV energy band at Galactic longitudes 72°≤ l ≤ 88°and latitudes |b| ≤ 15°.
We modeled the spatial and spectral distributions of the interstellar radiation (15, 16) as a linear combination of gas contributions from different clouds seen along the lines of sight in the atomic, molecular, and dark neutral gas phases ( fig. S1 ). We added a contribution from the largescale Galactic inverse Compton (IC) emission, an isotropic intensity for the instrumental and extragalactic backgrounds, and several noninterstellar sources such as pulsars and supernova remnants. In particular, we detected hard emission above 3 GeV from g Cygni (figs. S2 and S3), and the extended source was added to the background model (Fig. 2) .
The 0.1-to 100-GeV data indicate that the 8 million solar masses of gas of the whole Cygnus complex are, on average, pervaded by the same CR flux and spectrum as near the Sun (15), to within 20%. In the central regions, toward Cygnus X, the molecular clouds may exhibit a slightly harder spectrum above 10 GeV than the surrounding atomic clouds, but the deviation significance is <3s (15), so our background model assumes the same spectrum in all gas phases unless otherwise mentioned.
We find an extended excess of hard emission above the modeled background (Fig. 2C) . The excess fades out below 1 GeV because of the steep rise of the softer gas components (15). To measure the significance and spectrum of the excess, we fitted a Gaussian source with free location and width. The best fit (l = 79.6°T 0.3°, b = 1.4°T 0.4°, s = 2.0°T 0.2°) ( fig. S4 ) yields a 10.1 s detection above 1 GeV. We get a comparable significance and consistent morphology www.sciencemag.org SCIENCE VOL 334 25 NOVEMBER 2011 
